Articles related to Immunotherapy
Highlights of Moffitt Science Presented at Tandem Meetings of ASTCT and CIMBTR
Moffitt scientists are presenting advances in areas like cellular immunotherapy for relapsed or refractory (R/R) acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), acute lymphoblastic leukemia (ALL), lymphoma, multiple myeloma (MM) and allogeneic HCT. Read More
Clinscience and OncoBay Clinical Partner to Expand Immuno-Oncology Research Globally
The Polish clinical research organization Clinscience made a major investment in OncoBay to partner on projects in the U.S. and Europe Read More
Spreading Hope and Building on Faith Through A Cancer Journey
Celebrating a Life of Ministry and a Multiple Myeloma Milestone with a Very Special Patient Read More
A Unique Take on Customized Cancer Care
Husband, father and coffee aficionado Gary has become one of the first 100 patients to be treated with CAR T therapy approved for myeloma Read More
Cellular Immunotherapy Highlights from ASCO
Moffitt’s physicians and scientists were proud to share and present their cellular immunotherapy research findings at American Society of Clinical Oncology (ASCO 2022) Read More
New Non-Small Cell Lung Cancer Biomarkers Found
New non-small cell lung cancer biomarker: Distinct ecologies exist between disease that does and does not progress. Read More
Promises of Cell Therapy Bring Opportunities for Collaboration and Clinical Excellence
Finding ways to act on discrete targets on or within cancerous cells without affecting healthy cells is a key focus of several Moffitt research efforts. Read More
TIL Immunotherapy Offers Promising Results in Metastatic Non-Small Cell Lung Cancer
A group of investigators at Moffitt Cancer Center initiated a trial to determine if non-small cell lung cancer patients could have response to TIL therapy Read More
Immunotherapy Clinical Trial Brought Renewed Hope To Lung Cancer Patient
My husband and I celebrated our 50th wedding anniversary last year and know without a doubt that I would not be alive today if we had not sought treatment at Moffitt Cancer Center. Read More
Moffitt Treats First U.S. Patient with Newly FDA-Approved CAR T Therapy
Moffitt has treated the first U.S. adult lymphoma patient with a therapy formerly available only through clinical trials. Read More
Infographic: How CAR T Therapy Works to Fight Cancer
CAR T therapy, a groundbreaking new treatment, utilizes the body’s own immune system to fight cancer. Read More
What is CAR T Therapy?
Dr. Frederick Locke, vice chair of the Department of Blood and Marrow Transplant and Cellular Immunotherapy, answers some frequently asked questions about CAR T cell therapy. Read More
CAR T Cancer Therapy a ‘Huge Breakthrough’ for Patients with Lymphoma
Moffitt patients with an aggressive type of lymphoma were among the first to benefit in clinical trials of a groundbreaking therapy. Read More
Research Spotlight: Dr. Abate-Daga Discusses the Progress of Immunotherapy
Dr. Daniel Abate-Daga's research is focused on the development of T cell-based immunotherapies for the treatment of cancer. Read More
Dr. Locke: CAR-T Cell Therapy a 'Revolution in Cancer Care'
Dr. Locke, the principal investigator for a new experimental immunotherapy called CAR T-cell therapy, talks about the breakthroughs with this type of treatment. Read More
